Our data suggest that DAPK3 inhibition could be an alternative to ibrutinib treatment in CLL, particularly in cases where resistance is associated with BTK/ PLCγ2 mutations, but also more generally in cancers characterised by DAPK1‐silencing, which is a common marker of poor prognosis. Here, DAPK3 is linked to cancer.